In a study presented at a meeting of women’s cancer specialists, overall survival for women who received standard chemotherapy treatment plus bevacizumab was a median five months longer than for women who received the standard chemotherapy treatment alone.

READ FULL ARTICLE Curated publisher From Medical Express